Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
BioNTech’s Covid-19 vaccine, jointly developed with Pfizer, should be available to 12- to 15-year-olds in Europe from June, the chief executive of the German company has said.
Uğur Şahin said BioNTech had submitted its application for emergency approval of vaccines for this age group in the US at the start of April, and next Wednesday would be ready to submit the application for approval by the European Medicines Agency.
The Pfizer/BioNTech vaccine is already approved in the US and the EU for those 16 years of age and older. Vaccinating children is seen as a crucial next step towards herd immunity and ending the pandemic.
The prospect of getting older children inoculated before the next school year starts would also relieve the strain on parents, who are juggling the demands of homeschooling while keeping up with jobs.
Uğur Şahin said BioNTech had submitted its application for emergency approval of vaccines for this age group in the US at the start of April, and next Wednesday would be ready to submit the application for approval by the European Medicines Agency.
The Pfizer/BioNTech vaccine is already approved in the US and the EU for those 16 years of age and older. Vaccinating children is seen as a crucial next step towards herd immunity and ending the pandemic.
The prospect of getting older children inoculated before the next school year starts would also relieve the strain on parents, who are juggling the demands of homeschooling while keeping up with jobs.
Pfizer/BioNTech Covid jab may be offered to 12-year-olds in Europe from June
BioNTech submitting applications in US and Europe for vaccine to be available to those aged 12-15
www.theguardian.com